OncoCyte Corp.

As of September 8, 2025, OncoCyte Corp. shows a mildly bearish trend with mixed technical indicators, having outperformed the S&P 500 recently but with significantly negative long-term returns.

As of March 24, 2025, OncoCyte Corp. is considered a risky investment due to its high Price to Book Value of 8.31 and negative EV to EBIT of -2.37, despite a strong year-to-date return of 41.60%, overshadowed by an 87.96% decline over the past five years.

As of March 24, 2025, OncoCyte Corp. is considered "risky" and overvalued due to concerning financial metrics, including a price-to-book value of 8.31 and an ROE of -225.22%, which are worse than its peers, despite a strong year-to-date return of 53.78%.

As of June 20, 2025, OncoCyte Corp. has shifted to a bullish trend with moderate strength, supported by a bullish MACD and moving average, despite some mixed signals from KST and Dow Theory.

As of March 2022, the management team of OncoCyte Corp. includes Mr. Cavan Redmond (Independent Chairman), Mr. Ronald Andrews (President and CEO), and Independent Directors Mr. Andrew Arno, Ms. Melinda Griffith, and Dr. Andrew Last. They oversee the company's strategic direction and operations.

OncoCyte Corporation is a development-stage biotechnology company specializing in molecular cancer diagnostics, with a market cap of $91.52 million and recent net sales of $2 million, but a net loss of $7 million. The company has no dividend yield and significant negative return on equity.

As of Jun 18, OncoCyte Corp. has a market capitalization of 91.52 million, with net sales of 3.85 million and a net profit of -58.20 million over the last four quarters. As of Dec 24, shareholder's funds are at -12.27 million and total assets are 35.08 million.